Page last updated: 2024-08-23

alovudine and sirolimus

alovudine has been researched along with sirolimus in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brepoels, L; De Groot, T; De Wolf-Peeters, C; Mortelmans, L; Stroobants, S; Verhoef, G1
Aide, N; Cullinane, C; Dorow, D; Hicks, RJ; Kinross, K; McArthur, G; Neels, O; Roselt, P; Waldeck, K1
Aichler, M; Baumgart, A; Buck, A; Dechow, T; Feuchtinger, A; Graf, N; Herrmann, K; Jünger, A; Keller, U; Li, Z; Peschel, C; Schwaiger, M; Walch, A1
Boerman, OC; Fleuren, ED; Flucke, UE; Franssen, GM; Houghton, PJ; Oyen, WJ; Roeffen, MH; van der Graaf, WT; Versleijen-Jonkers, YM1

Other Studies

4 other study(ies) available for alovudine and sirolimus

ArticleYear
(18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009, Volume: 50, Issue:7

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cyclophosphamide; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Lymphoma; Metabolic Clearance Rate; Mice; Mice, SCID; Protein Kinase Inhibitors; Protein Kinases; Radionuclide Imaging; Radiopharmaceuticals; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases; Treatment Outcome

2009
18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:10

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Dideoxynucleosides; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome

2010
FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
    Cancer research, 2012, Oct-01, Volume: 72, Issue:19

    Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Survival; Dideoxynucleosides; Enzyme Inhibitors; Everolimus; Female; Flow Cytometry; Fluorine Radioisotopes; Fluorodeoxyglucose F18; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lymphoma, Large-Cell, Anaplastic; Mice; Mice, SCID; Positron-Emission Tomography; Protein-Tyrosine Kinases; Resorcinols; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays

2012
Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
    International journal of cancer, 2014, Dec-15, Volume: 135, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Positron-Emission Tomography; Protein Kinase Inhibitors; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2014